BLU News and Press, BELLUS Health Inc. From 04/24/23

2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...

2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...

2023-04-20 14:36:15 ET Shares of Bellus Health (NASDAQ: BLU) jumped 105.1% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence . The company, which received a $2 billion buyout offer from GSK (formerly known as GlaxoSmithKline...

2023-04-19 09:01:34 ET With several large M&A deals involving biotechs being acquired so far in 2023, RBC Capital Markets says such activity could be on the rise ahead. Given recent M&A activity, we "remind investors that there remains M&A appetite among large pharmas,...

2023-04-18 13:37:57 ET Shares of Bellus Health Inc ( NASDAQ: BLU ) almost doubled this morning after GSK plc ( LON: GSK ) said it will buy the biopharmaceutical company for about $2.0 billion. Details of the announced acquisition The all-cash agreement values Bellus Heal...

2023-04-18 12:50:32 ET Gainers: BELLUS Health ( BLU ) +98% . Dermata Therapeutics ( DRMA ) +68% . Gamida Cell ( GMDA ) +53% . Allarity Therapeutics ( ALLR ) +45% . Esports Entertainment Group ( GMBL ) +35% . Altamira Therapeu...

Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough Currently in phase III clinical development with anticipated regulatory approval and launch in 2...

BELLUS Health Inc. (NASDAQ: BLU) is one of today's top gainers. The company's shares are currently up 98.42% on the day to $14.4. BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensi...

2023-04-18 11:33:17 ET Shares of BELLUS Health (NASDAQ: BLU) were up by a whopping 98.9% as of 10:19 a.m. ET Tuesday morning. The big gain came in response to a $2 billion buyout agreement with British pharma giant GSK (NYSE: GSK) . Per the terms of the deal, GSK has agr...

2023-04-18 10:04:36 ET Gainers: Dermata Therapeutics ( DRMA ) +108% . BELLUS Health ( BLU ) +99% . Allarity Therapeutics ( ALLR ) +69% . Gamida Cell ( GMDA ) +37% . YS Biopharma ( YS ) +28% . Losers: China Jo-Jo Drugs...